Physician profile
Wojciech Poluha
NPI 1164409231
$1,108.22
in general payments reported to CMS, 2019-2025
15 companies · $418 in 2025
The $418 reported for 2025 was more than what 77% of Addiction Medicine (Internal Medicine) providers received nationally (typical 2025 total: $124).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $194 · 2021: $96.90 · 2022: $58.18 · 2023: $185 · 2024: $50.19 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $653.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $334.45 | 2019-2025 | Sublocade |
| Pfizer INC. | $149.19 | 2020-2025 | |
| Exact Sciences Corporation | $124.71 | 2023-2025 | Cologuard Collection Kit |
| Alkermes, INC. | $108.68 | 2024-2025 | Vivitrol |
| Otsuka America Pharmaceutical, INC. | $71.63 | 2022-2023 | Rexulti |
| Abbvie INC. | $63.27 | 2021-2025 | |
| Braeburn INC. | $42.65 | 2025 | Brixadi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.86 | 2019 | |
| Orexo US, INC. | $36.52 | 2020 | |
| Lilly USA, LLC | $29.96 | 2023 | Mounjaro |
| Pear Therapeutics (US), INC. | $24.86 | 2021 | |
| Allergan, INC. | $23.30 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.25 | 2023 | |
| Novo Nordisk INC | $17.78 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $17.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wojciech Poluha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.